



Stroke Journal &lt;stroke@strokeahajournal.org&gt;

---

**MS ID#: STROKE/2020/030565R1**

1 message

**Yamauchi, Michael** <Michael.Yamauchi@alexion.com>

Thu, Dec 17, 2020 at 3:44 PM

To: "stroke@strokeahajournal.org" &lt;stroke@strokeahajournal.org&gt;

Cc: "Schaefer, Melanie" &lt;Melanie.Schaefer@alexion.com&gt;, "kmccconnell@cellohealth.com" &lt;kmccconnell@cellohealth.com&gt;, "ademchuk@ucalgary.ca" &lt;ademchuk@ucalgary.ca&gt;

Dear Editorial Office,

I'm writing in reference to the manuscript titled "Hemostatic Efficacy and Anti-FXa Reversal with Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy" (MS ID#: STROKE/2020/030565R1) currently under review at Stroke. The authors have permission from Alexion Pharmaceuticals, Inc. to publish the paper.

Also please use the following copyright line: Copyright Portola Pharmaceuticals Inc., a subsidiary of Alexion Pharmaceuticals Inc. and the authors.

Regards,

**Michael Yamauchi, Ph.D.**  
*Sr. Director, Patent Counsel*

**Alexion Pharmaceuticals, Inc.**

121 Seaport Boulevard

Boston, MA 02210

**direct** (857) 338-8776**mobile** (203) 645-0975**email** [Michael.Yamauchi@alexion.com](mailto:Michael.Yamauchi@alexion.com)

---

CONFIDENTIALITY NOTICE -- This communication, including any attachments, is for the exclusive use of the intended recipient and may contain proprietary, confidential or privileged information. If you are not the intended recipient, any use, copying, disclosure, dissemination or distribution is strictly prohibited. If there is any reason to believe you are not the intended recipient, please notify the sender immediately by return email and delete this communication and destroy all copies. Thank you.

